Targeting Hepatic Glucose Metabolism in the Treatment of Type 2 Diabetes

Nat Rev Drug Discov. 2016 Nov;15(11):786-804. doi: 10.1038/nrd.2016.151. Epub 2016 Aug 12.

Abstract

Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis, resulting in hyperglycaemia. Although current diabetes treatments have exhibited some success in lowering blood glucose levels, their effect is not always sustained and their use may be associated with undesirable side effects, such as hypoglycaemia. Novel antidiabetic drugs, which may be used in combination with existing therapies, are therefore needed. The potential of specifically targeting the liver to normalize blood glucose levels has not been fully exploited. Here, we review the molecular mechanisms controlling hepatic gluconeogenesis and glycogen storage, and assess the prospect of therapeutically targeting associated pathways to treat type 2 diabetes.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism*
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Glucose / antagonists & inhibitors
  • Glucose / metabolism*
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Liver / drug effects
  • Liver / metabolism*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology

Substances

  • Hypoglycemic Agents
  • Glucose